| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
cardiotrophin 2, pseudogene |
|
phenotype | 0.100 | None | 1.000 | 2 | 1 | 2010 | 2013 | |||||||||||
|
C1orf167 antisense RNA 1 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | |||||||||||
|
long intergenic non-protein coding RNA 1257 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | |||||||||||
|
ring finger protein 214 | 0.91 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||||
|
haloacid dehalogenase like hydrolase domain containing 5 | 1.3E-09 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2017 | 2017 | ||||||||||
|
polypeptide N-acetylgalactosaminyltransferase like 6 | 4.3E-09 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||||
|
CTD small phosphatase like 2 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2019 | 2019 | ||||||||||
|
chromosome 8 open reading frame 58 | 4.6E-05 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||||
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 | 7.7E-07 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2019 | 2019 | ||||||||||
|
nucleoporin 210 like | 3.2E-04 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||||
|
BCL2 apoptosis regulator | 0.291 | 0.885 | 0.56 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2012 | 2018 | ||||||||
|
apolipoprotein E | 0.338 | 0.962 | 1.9E-03 |
|
phenotype | 0.100 | None | 1.000 | 3 | 5 | 2012 | 2019 | ||||||||
|
major histocompatibility complex, class I, B | 0.379 | 0.885 | 3.9E-05 |
|
phenotype | 0.100 | None | 1.000 | 3 | 4 | 2010 | 2018 | ||||||||
|
cyclin dependent kinase inhibitor 1A | 0.403 | 0.769 | 1.9E-03 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2012 | 2018 | ||||||||
|
caspase 8 | 0.404 | 0.923 | 3.7E-06 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2017 | 2017 | ||||||||
|
SMAD family member 3 | 0.415 | 0.923 | 0.80 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
major histocompatibility complex, class II, DQ alpha 1 | 0.416 | 0.846 | 2.4E-02 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
insulin receptor | 0.432 | 0.846 | 3.6E-05 |
|
phenotype | 0.100 | None | 1.000 | 5 | 4 | 2012 | 2019 | ||||||||
|
dopamine receptor D2 | 0.436 | 0.846 | 0.75 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
neurofibromin 1 | 0.440 | 0.885 | 0.90 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
lipoprotein(a) | 0.444 | 0.769 | 6.6E-89 |
|
phenotype | 0.100 | None | 1.000 | 2 | 2 | 2012 | 2018 | ||||||||
|
TIMP metallopeptidase inhibitor 3 | 0.445 | 0.923 | 0.63 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2019 | 2019 | ||||||||
|
collagen type XVIII alpha 1 chain | 0.449 | 0.808 | 1.7E-10 |
|
phenotype | 0.100 | None | 1.000 | 2 | 1 | 2014 | 2018 | ||||||||
|
apolipoprotein B | 0.453 | 0.808 | 1.9E-16 |
|
phenotype | 0.100 | None | 1.000 | 6 | 8 | 2007 | 2019 | ||||||||
|
AT-rich interaction domain 1A | 0.455 | 0.846 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2019 | 2019 |